Skip to content
Screener

Rigel Pharmaceuticals RIGL Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$101.7MBeat by $39.4M
EPS$3.28Beat by $1.31
Revenue estimate$62.3M
EPS estimate$1.97

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$80.1M
EPS estimate$0.92

Financials

Q2 2025

Income statement

See full
Revenue$101.7M+176%
Gross profit$97.2M+186%
Operating income$61.1M+13,570%
Net income$59.6M+5,888%
EPS (diluted)$3.28+5,567%

Balance sheet

See full
Cash & equivalents$53.4M+48.1%
Total debt$1.2M+92.6%
Total equity$81.9M+374%
Total assets$206.7M+61.0%

Cash flow

See full
Operating cash flow$30.5M+10,012%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$334.21M+132%
Enterprise value$282.04M+159%
P/E3.4×—
P/S1.2×+0.1×

Profitability

See full
Gross margin91.5%-0.9pp
Operating margin39%+33.1pp
Net margin36.5%+29.5pp

Returns & leverage

See full
Debt / equity0×—
Current ratio2×+0.4×

Segments

By product

See full
Gross product sales$79.7M+62.7%
Delivery of drug supplies, royalties and others$2.8M-18.7%
Discounts and allowances-$20.7M-33.6%

FAQ

When did Rigel Pharmaceuticals report Q2 2025 earnings?
Rigel Pharmaceuticals (RIGL) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Rigel Pharmaceuticals's Q2 2025 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $101.7M and eps of $3.28 for Q2 2025.
Did Rigel Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $62.3M by $39.4M. EPS beat the consensus estimate of $1.97 by $1.31.
How did Rigel Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 176.0% from $36.8M a year earlier.
Where can I find Rigel Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-074163) and the 10-Q periodic report (0001558370-25-010281) directly on SEC EDGAR. The filing index links above go to sec.gov.